Literature DB >> 21711424

Ursodeoxycholic acid dose-dependently improves liver injury in rats fed a methionine- and choline-deficient diet.

Vyacheslav U Buko1, Irina A Kuzmitskaya-Nikolaeva, Elena E Naruta, Oksana Y Lukivskaya, Siarhei N Kirko, Horst-Dietmar Tauschel.   

Abstract

AIM: The data on the beneficial effect of ursodeoxycholic acid (UDCA) in non-alcoholic steatohepatitis (NASH) are controversial. The difference of opinion is connected with UDCA dosage to be used. Therefore, we evaluated the dose-dependent efficacy of UDCA in experimental NASH.
METHODS: Male Wistar rats were fed the methionine- and choline-deficient (MCD) diet for 10 weeks. Rats were administrated UDCA (10, 20, 40 and 80 mg/kg bodyweight intragastrically) after 6 weeks of the MCD diet.
RESULTS: Animals fed the MCD diet developed severe steatohepatitis. Treatment with UDCA dose-dependently decreased liver damage, but only high-dose UDCA (80 mg/kg) significantly diminished ultrastructural changes in addition to preventing steatosis, ballooning and inflammatory changes in the liver. The activities of serum marker enzymes and the content of liver triglyceride and blood glucose were increased in MCD diet-fed rats, but decreased in all the UDCA-treated groups. Serum insulin concentration was decreased whereas the quantitative insulin sensitivity check index did not changed in MCD diet-fed groups. Serum tumor necrosis factor-α content was strongly increased after MCD diet and normalized in the UDCA-treated rats, with the most pronounced effect in the highest dose groups, 40 and 80 mg/kg. The contents of endogenous ethanol in blood and intestinal mucus were increased in MCD diet-fed rats which were significantly lowered by UDCA (40 and 80 mg/kg per day).
CONCLUSION: The present data demonstrate a beneficial effect of UDCA that manifested by the decrease of liver steatosis, inflammatory signs and serum tumor necrosis factor-α content especially of the highest 40 and 80 mg/kg day doses.
© 2011 The Japan Society of Hepatology.

Entities:  

Year:  2011        PMID: 21711424     DOI: 10.1111/j.1872-034X.2011.00820.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  11 in total

1.  Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist.

Authors:  Kyosuke Fujita; Yusuke Iguchi; Mizuho Une; Shiro Watanabe
Journal:  Lipids       Date:  2017-03-17       Impact factor: 1.880

2.  Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver Fibrosis.

Authors:  Vyacheslav U Buko; Oxana Y Lukivskaya; Elena E Naruta; Elena B Belonovskaya; Horst-Dietmar Tauschel
Journal:  J Clin Exp Hepatol       Date:  2014-02-21

3.  Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.

Authors:  Tadashi Namisaki; Ryuichi Noguchi; Kei Moriya; Mitsuteru Kitade; Yosuke Aihara; Akitoshi Douhara; Norihisa Nishimura; Kosuke Takeda; Yasushi Okura; Hideto Kawaratani; Hiroaki Takaya; Kenichiro Seki; Hitoshi Yoshiji
Journal:  J Gastroenterol       Date:  2015-07-21       Impact factor: 7.527

4.  The effects of ursodeoxycholic acid on sepsis-induced cholestasis management in an animal model.

Authors:  Randa H Ainosah; Magda M Hagras; Sameer E Alharthi; Omar I Saadah
Journal:  J Taibah Univ Med Sci       Date:  2020-06-27

5.  Changes in Bile Acid Profile After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Metabolic Profile and Fatty Liver Disease.

Authors:  Ajay P Belgaumkar; Royce P Vincent; Kirstin A Carswell; Robin D Hughes; Jamie Alaghband-Zadeh; Ragai R Mitry; Carel W le Roux; Ameet G Patel
Journal:  Obes Surg       Date:  2016-06       Impact factor: 4.129

Review 6.  The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review.

Authors:  Zun Xiang; Yi-peng Chen; Kui-fen Ma; Yue-fang Ye; Lin Zheng; Yi-da Yang; You-ming Li; Xi Jin
Journal:  BMC Gastroenterol       Date:  2013-09-23       Impact factor: 3.067

7.  Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model.

Authors:  Hu Li; Qingling Wang; Peizhan Chen; Chenghua Zhou; Xinxin Zhang; Li Chen
Journal:  Front Pharmacol       Date:  2021-12-06       Impact factor: 5.810

8.  An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients.

Authors:  Pathik Parikh; Meghraj Ingle; Jatin Patel; Prasad Bhate; Vikas Pandey; Prabha Sawant
Journal:  Saudi J Gastroenterol       Date:  2016 May-Jun       Impact factor: 2.485

9.  Ursodeoxycholate Restores Biliary Excretion of Methotrexate in Rats with Ethinyl Estradiol Induced-Cholestasis by Restoring Canalicular Mrp2 Expression.

Authors:  Min Ju Kim; Yun Ju Kang; Mihwa Kwon; Young A Choi; Min-Koo Choi; Hye-Young Chi; Hye Hyun Yoo; Chang-Koo Shim; Im-Sook Song
Journal:  Int J Mol Sci       Date:  2018-04-09       Impact factor: 5.923

Review 10.  Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.

Authors:  Richard Radun; Michael Trauner
Journal:  Semin Liver Dis       Date:  2021-07-21       Impact factor: 6.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.